Compare CNX & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNX | IOVA |
|---|---|---|
| Founded | 1860 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 1.4B |
| IPO Year | 1998 | 2008 |
| Metric | CNX | IOVA |
|---|---|---|
| Price | $38.51 | $3.44 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $35.71 | $9.11 |
| AVG Volume (30 Days) | 1.9M | ★ 14.3M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 763.33 | 14.84 |
| EPS | ★ 3.98 | N/A |
| Revenue | ★ $2,239,134,000.00 | N/A |
| Revenue This Year | N/A | $51.55 |
| Revenue Next Year | $11.01 | $37.55 |
| P/E Ratio | $9.71 | ★ N/A |
| Revenue Growth | ★ 76.76 | N/A |
| 52 Week Low | $27.68 | $1.64 |
| 52 Week High | $43.62 | $5.63 |
| Indicator | CNX | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 40.43 | 44.16 |
| Support Level | $36.33 | $2.02 |
| Resistance Level | $42.50 | $4.34 |
| Average True Range (ATR) | 1.63 | 0.25 |
| MACD | -0.36 | -0.11 |
| Stochastic Oscillator | 18.29 | 19.21 |
CNX Resources Corp is an independent natural gas development, production, midstream and technology company centered in the Appalachian Basin. It is focused on unconventional shale formations, prominently the Marcellus Shale and Utica Shale, in Pennsylvania, Ohio and West Virginia. Additionally, the company operates and develops Coalbed Methane (CBM) properties in Virginia. the company has two reportable segments: Shale and Coalbed Methane. The majority of the company's revenue is derived from the Shale segment.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.